8-K: Protagenic Therapeutics Faces Nasdaq Delisting Warning Over Delayed Annual Meeting

Protagenic Therapeutics receives a notification from Nasdaq regarding non-compliance with listing rules due to a delay in holding its annual shareholder meeting.

Summary

• Protagenic Therapeutics, Inc. received a notification from Nasdaq on January 15, 2025, regarding its failure to hold an annual meeting of shareholders within twelve months of the end of its December 31, 2023 fiscal year.
• This is a violation of Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G).
• The company has scheduled its annual meeting to occur no later than February 21, 2025.
• The company is in ongoing discussions with the Nasdaq Hearings Panel regarding its listing status and will address this matter in its presentation to the Panel.
• The notification letter has no immediate effect on the listing of the company's securities on the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the Nasdaq notification and potential delisting concerns, but the company is taking steps to address the issue.

Positives

• The notification letter has no immediate effect on the listing of the company's securities on the Nasdaq Capital Market.
• The company has already scheduled its annual meeting to occur no later than February 21, 2025.

Negatives

• Protagenic Therapeutics is in violation of Nasdaq Listing Rules 5620(a) and 5810(c)(2)(G) due to the delayed annual meeting.

Risks

• Failure to hold the annual meeting by February 21, 2025, could lead to further delisting actions by Nasdaq.
• The ongoing discussions with the Nasdaq Hearings Panel indicate potential underlying issues with the company's listing status.

Future Outlook

The company remains focused on meeting all listing requirements in the normal course of business.

Management Comments

• The Company has already scheduled its annual meeting to occur no later than February 21, 2025, and is committed to addressing this compliance matter.

Industry Context

Many companies face challenges in maintaining compliance with exchange listing requirements, especially smaller companies or those undergoing significant changes.

Stakeholder Impact

• Shareholders may be concerned about the potential delisting from Nasdaq.
• Employees may experience uncertainty due to the company's compliance issues.

Next Steps

• Protagenic Therapeutics needs to hold its annual meeting no later than February 21, 2025.
• The company will continue discussions with the Nasdaq Hearings Panel regarding its listing status.

Key Dates